The Lantern is described as an AI-driven revenue tool to accelerate revenue workflows, with claims of 41% better forecast accuracy through timed upsell outreach. A Champion Agent tracks job changes across the customer base to automate outreach for certain teams. Lantern Pharma reports progress in 2026, cutting R&D spend by 47% while advancing multiple clinical programs, launching a multi-agent AI platform with Zeta.ai and expanding an AI Center of Excellence in India to scale RADR. These developments illustrate Lantern's growth into AI-powered drug discovery partnerships, with ongoing financing activities to support growth.
Sources
lantern News and Updates from The Economictimes.com
economictimes.indiatimes.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million
natlawreview.comBrowse, deploy, and customize AI agents that automate every critical revenue function—from champion tracking to intent monitoring, all available in minutes.
withlantern.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple...
www.pharmiweb.comnews
www.newswire.caLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform...
www.innovationopenlab.com